⌘K

Login Start Free

Home/Filings/4/0000950170-25-087947

4//SEC Filing

Collier Kathryn J 4

Accession 0000950170-25-087947

CIK 0001505512other

View on SEC.gov Company Profile

Filed

Jun 17, 8:00 PM ET

Accepted

Jun 18, 5:00 PM ET

Size

13.2 KB

Accession

0000950170-25-087947

Insider Transaction Report

Form 4

Period: 2025-06-16

Regulus Therapeutics Inc.RGLS

Collier Kathryn J

Director

Transactions

Exercise/Conversion
Common Stock
2025-06-17$9.90/sh+2,604$25,780→ 65,240 total
Exercise/Conversion
Common Stock
2025-06-16$9.90/sh+1,396$13,820→ 67,844 total
Exercise/Conversion
Common Stock
2025-06-17$8.80/sh+2,325$20,460→ 62,915 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-06-17−2,325→ 0 total
Exercise: $8.80From: 2021-06-14Exp: 2030-06-16→ Common Stock (2,325 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-06-16−1,396→ 2,604 total
Exercise: $9.90From: 2022-06-09Exp: 2031-06-13→ Common Stock (1,396 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-06-17−2,604→ 0 total
Exercise: $9.90From: 2022-06-09Exp: 2031-06-13→ Common Stock (2,604 underlying)

Documents

1 file

4
ownership.xmlPrimary
4

Issuer

Regulus Therapeutics Inc.

CIK 0001505512

Entity typeother

Related Parties

1

filerCIK 0001737436

Filing Metadata

Form type: 4
Filed: Jun 17, 8:00 PM ET
Accepted: Jun 18, 5:00 PM ET
Size: 13.2 KB

View on SEC.gov